GSE217452 docetaxel 2 v 0 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE217452_docetaxel_2_v_0_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE217452_docetaxel_2_v_0_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE217452_docetaxel_2_v_0_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE217452_docetaxel_2_v_0_human_up.

Results found

Linked to

 

Label

Description

 

Gene

small nucleolar RNA host gene 3

Gene

PAX8 antisense RNA 1

Gene

long intergenic non-protein coding RNA 1291

Gene

long intergenic non-protein coding RNA, p53 induced transcript

Gene

embryonic stem cell related

Gene

AFAP1 antisense RNA 1

Gene

long intergenic non-protein coding RNA 2582

Gene

SOX21 antisense RNA 1

Gene

DPH5 divergent transcript

Gene

family with sequence similarity 66 member B

  • Gene

    small nucleolar RNA host gene 3


  • Gene

    PAX8 antisense RNA 1


  • Gene

    long intergenic non-protein coding RNA 1291


  • Gene

    long intergenic non-protein coding RNA, p53 induced transcript


  • Gene

    embryonic stem cell related


  • Gene

    AFAP1 antisense RNA 1


  • Gene

    long intergenic non-protein coding RNA 2582


  • Gene

    SOX21 antisense RNA 1


  • Gene

    DPH5 divergent transcript


  • Gene

    family with sequence similarity 66 member B

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.